Agentix Corp. (AGTX)
USD 0.05
(-35.88%)
USD 0.05
(-35.88%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.51 Million USD | 0.0% |
| 2021 | 69.28 Thousand USD | -44.96% |
| 2020 | 125.87 Thousand USD | 0.0% |
| 2018 | 55.39 Thousand USD | -23.24% |
| 2017 | 72.17 Thousand USD | 1856.44% |
| 2016 | 3689.00 USD | -49.95% |
| 2015 | 7370.00 USD | -62.3% |
| 2014 | 19.55 Thousand USD | 95.51% |
| 2013 | 10 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 2.98 Million USD | 18.82% |
| 2023 Q4 | 2.51 Million USD | 27.14% |
| 2023 FY | 2.51 Million USD | 0.0% |
| 2023 Q1 | 1.25 Million USD | 20.73% |
| 2023 Q2 | 1.62 Million USD | 29.68% |
| 2023 Q3 | 1.97 Million USD | 21.55% |
| 2022 Q4 | 1.03 Million USD | 34.2% |
| 2022 Q3 | 773.16 Thousand USD | 27.39% |
| 2022 Q2 | 606.94 Thousand USD | 63.99% |
| 2022 Q1 | 370.11 Thousand USD | 27.67% |
| 2021 FY | 69.28 Thousand USD | -44.96% |
| 2021 Q1 | 43.7 Thousand USD | 48.93% |
| 2021 Q2 | 69.28 Thousand USD | 58.54% |
| 2021 Q3 | 54.33 Thousand USD | -21.58% |
| 2021 Q4 | 289.91 Thousand USD | 433.52% |
| 2020 FY | 125.87 Thousand USD | 0.0% |
| 2020 Q1 | 109.22 Thousand USD | 11.18% |
| 2020 Q2 | 125.87 Thousand USD | 15.25% |
| 2020 Q3 | 17.59 Thousand USD | -86.02% |
| 2020 Q4 | 29.34 Thousand USD | 66.79% |
| 2019 Q3 | 81.5 Thousand USD | 47.13% |
| 2019 Q2 | 55.39 Thousand USD | 31.51% |
| 2019 Q4 | 98.24 Thousand USD | 20.53% |
| 2019 Q1 | 42.12 Thousand USD | -60.98% |
| 2018 Q3 | 87.68 Thousand USD | 21.5% |
| 2018 Q4 | 107.95 Thousand USD | 23.11% |
| 2018 FY | 55.39 Thousand USD | -23.24% |
| 2018 Q1 | 49.63 Thousand USD | -82.93% |
| 2018 Q2 | 72.17 Thousand USD | 45.41% |
| 2017 Q3 | 173.7 Thousand USD | 4608.76% |
| 2017 FY | 72.17 Thousand USD | 1856.44% |
| 2017 Q1 | 882.00 USD | 1.38% |
| 2017 Q2 | 3689.00 USD | 318.25% |
| 2017 Q4 | 290.84 Thousand USD | 67.43% |
| 2016 Q4 | 870.00 USD | 13.58% |
| 2016 Q2 | 7370.00 USD | 276.79% |
| 2016 FY | 3689.00 USD | -49.95% |
| 2016 Q1 | 1956.00 USD | -91.15% |
| 2016 Q3 | 766.00 USD | -89.61% |
| 2015 Q4 | 22.1 Thousand USD | 56.51% |
| 2015 FY | 7370.00 USD | -62.3% |
| 2015 Q3 | 14.12 Thousand USD | -27.77% |
| 2015 Q2 | 19.55 Thousand USD | 0.0% |
| 2014 FY | 19.55 Thousand USD | 95.51% |
| 2013 FY | 10 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -9051.588% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 73.478% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 96.536% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -210.407% |
| Rebus Holdings, Inc. | 5.24 Million USD | 52.107% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 95.746% |
| Qrons Inc. | 1.48 Million USD | -68.639% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -104.741% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 96.649% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -5516.957% |
| Skye Bioscience, Inc. | 14.07 Million USD | 82.16% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 95.29% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 73.799% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -495.528% |
| SQZ Biotechnologies Company | 50.03 Million USD | 94.983% |
| Intellipharmaceutics International Inc. | 12 Million USD | 79.094% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 34.815% |
| Mesoblast Limited | 188.44 Million USD | 98.668% |
| Marizyme, Inc. | 26.67 Million USD | 90.589% |
| Genus plc | 485 Million USD | 99.482% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 57.03% |
| Pharming Group N.V. | 244.07 Million USD | 98.971% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -24.895% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | 0.229% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 33.933% |
| ContraFect Corporation | 32.53 Million USD | 92.283% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -26.712% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 34.41% |
| IMV Inc. | 37.93 Million USD | 93.382% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 78.685% |
| MultiCell Technologies, Inc. | 1617.67 USD | -155095.744% |
| ONE Bio Corp. | 27.49 Million USD | 90.869% |
| Accustem Sciences Inc. | 1.07 Million USD | -132.623% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 96.757% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -18.698% |
| Q BioMed Inc. | 8.13 Million USD | 69.131% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 96.973% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 51.214% |
| Biomind Labs Inc. | 1.49 Million USD | -67.525% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 97.885% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 72.235% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 86.358% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -75.091% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -1666.814% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -1148.312% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 56.306% |
| GB Sciences, Inc. | 5.41 Million USD | 53.659% |
| Alpha Cognition Inc. | 7.16 Million USD | 64.96% |
| HST Global, Inc. | 593.59 Thousand USD | -322.942% |
| CSL Limited | 18.62 Billion USD | 99.987% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -99.378% |
| Halberd Corporation | 728.71 Thousand USD | -244.516% |
| Enzolytics Inc. | 365.26 Million USD | 99.313% |
| Resverlogix Corp. | 67.39 Million USD | 96.275% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -199.327% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 99.436% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -46.473% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 89.855% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 78.908% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 31.502% |
| AVAX Technologies, Inc. | 3.99 Million USD | 37.138% |
| Zenith Capital Corp. | 27.56 Thousand USD | -9006.442% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.811% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -951.964% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 32.771% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -268.747% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | 7.416% |
| Kadimastem Ltd | 3.5 Million USD | 28.369% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -3651.072% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 95.005% |
| BioStem Technologies, Inc. | 15.9 Million USD | 84.215% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -440.254% |
| LadRx Corporation | 2.2 Million USD | -14.089% |
| Cell Source, Inc. | 15.8 Million USD | 84.117% |
| Regen BioPharma, Inc. | 5.45 Million USD | 53.999% |
| Regen BioPharma, Inc. | 5.45 Million USD | 53.999% |
| NovAccess Global Inc. | 7.86 Million USD | 68.062% |
| Affymax, Inc. | 8.87 Million USD | 71.699% |
| Itoco Inc. | 1.65 Million USD | -51.865% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -22.373% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 58.496% |
| Mobile Lads Corp. | 1.31 Million USD | -91.135% |
| CytoDyn Inc. | 127.89 Million USD | 98.037% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -5906.256% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -60.278% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 77.27% |
| SYBLEU INC | 681.41 Thousand USD | -268.434% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 58.856% |
| International Stem Cell Corporation | 5.27 Million USD | 52.425% |
| Bioxytran, Inc. | 3.24 Million USD | 22.74% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -301.17% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 45.625% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 93.876% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 88.724% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -23.954% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 54.17% |
| Neutra Corp. | 973.52 Thousand USD | -157.882% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 91.347% |
| PureTech Health plc | 125.58 Million USD | 98.001% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 33.179% |
| IXICO plc | 1.9 Million USD | -32.114% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 87.771% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 97.57% |
| CSL Limited | 18.62 Billion USD | 99.987% |
| Cellectis S.A. | 249.36 Million USD | 98.993% |